GHK-Cu vs TB-500
A copper-based ingredient sold in skin creams and injections for wrinkles, hair loss and healing. It speeds wound healing in rats, but no proper human trial exists. It is sold as an injection for healing torn muscles and tendons. No study has tested it for injuries in people or animals.
Both sit at grade C: animal and cell studies. Neither is FDA approved.
Evidence
CAnimal and cell studies
CAnimal and cell studies
Human studies cited
Animal or cell studies cited
Why the grade
For skin repair and wound healing, the use GHK-Cu is best known for, the primary studies in hand are cell cultures and rat and mouse experiments, including a hair-growth study in fuzzy rats. The human cosmetic results that reviews describe come from manufacturer-run tests that are summarised and not published in full, so no controlled human trial with a known sample size can be named.
There are no published human trials of TB-500 itself. The only TB-500-specific papers are doping-control chemistry studies that identified the peptide in gray-market and veterinary products and detected it in horses. Human trials exist for full-length thymosin beta-4 (a venous-ulcer safety study planned for 72 patients and an 18-patient eye-drop trial), but those tested a different, larger molecule.
FDA
Not approved
GHK-Cu is not approved by the FDA for any use. As copper tripeptide-1 it is sold in cosmetics, which sit outside FDA drug approval. The FDA placed the injectable form in Category 2 of its compounding list in 2023 over safety risks, and the agency now lists that nomination as withdrawn; it plans to bring GHK-Cu before its Pharmacy Compounding Advisory Committee by the end of February 2027.
Not approved
TB-500 is not approved by the FDA for any use and is sold as a research chemical. In July 2026 an FDA advisory committee recommended it for the list of substances pharmacies may compound. On 28 October 2026 HHS issued an enforcement discretion policy covering TB-500 acetate for injection under the skin or into muscle. Licensed pharmacies and physicians may compound it for a named patient if they meet sourcing, testing, labeling and reporting conditions. That is not an approval, and the bulks list decision still needs a rule.
Sold for
GHK-Cu is sold as an anti-aging and wound-healing peptide, in serums for wrinkles and hair thinning and as an injectable for recovery.
TB-500 is sold online as an injectable healing peptide for torn muscles, tendons and ligaments, often paired with BPC-157.
Studies say
Cell and animal work shows that GHK-Cu raises collagen production and speeds wound closure in rats, but the human evidence is limited to cosmetic tests reported inside reviews, which is why the grade is C.
Nothing published tests TB-500 for injury in humans or animals; the evidence for its parent protein comes from small trials in wounds and the eye, so the grade is C.
Class
Copper-binding tripeptide
Synthetic Tβ4 fragment
Route
Several routes
Injection